Aminocaproic acid is an antifibrinolytic agent used as an adjunct therapy in patients with von Willebrand disease (VWD) to help prevent or control bleeding. Like tranexamic acid, it works by inhibiting fibrinolysis, the process that breaks down blood clots, thereby helping to stabilize clots that have already formed.

It is especially effective for mucosal bleeding (e.g., oral, nasal, or gynecologic) and is commonly used during dental procedures, minor surgeries, or to manage heavy menstrual bleeding. Aminocaproic acid is typically taken orally or intravenously, and is often used in combination with desmopressin or VWF concentrates in patients with VWD. It does not replace VWF or FVIII, but it plays a supportive role in improving hemostasis.